$0.92
6.40% today
Nasdaq, Apr 01, 06:44 pm CET
ISIN
US67577R1023
Symbol
IRD
Sector
Industry

Ocuphire Pharma Inc Stock price

$0.98
-0.05 4.68% 1M
-0.33 25.05% 6M
-0.21 17.50% YTD
-1.25 55.97% 1Y
-2.26 69.70% 3Y
-6.22 86.36% 5Y
-349.42 99.72% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.03 2.79%
ISIN
US67577R1023
Symbol
IRD
Sector
Industry

Key metrics

Market capitalization $43.46m
Enterprise Value $6.82m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.81
P/S ratio (TTM) P/S ratio 5.19
P/B ratio (TTM) P/B ratio 0.75
Revenue growth (TTM) Revenue growth -85.35%
Revenue (TTM) Revenue $8.38m
EBIT (operating result TTM) EBIT $-29.47m
Free Cash Flow (TTM) Free Cash Flow $-13.59m
Cash position $36.64m
EPS (TTM) EPS $-1.09
P/E forward negative
P/S forward 4.43
EV/Sales forward 0.80
Short interest 2.05%
Show more

Is Ocuphire Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Ocuphire Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Ocuphire Pharma Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Ocuphire Pharma Inc forecast:

Buy
100%

Financial data from Ocuphire Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.38 8.38
85% 85%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
32% 32%
169%
- Research and Development Expense 24 24
36% 36%
282%
-29 -29
201% 201%
-352%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -29 -29
201% 201%
-352%
Net Profit -27 -27
195% 195%
-324%

In millions USD.

Don't miss a Thing! We will send you all news about Ocuphire Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocuphire Pharma Inc Stock News

Neutral
GlobeNewsWire
one day ago
Provides update on the Company's transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases
Neutral
GlobeNewsWire
11 days ago
Believes that Current Board's Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction
Neutral
GlobeNewsWire
11 days ago
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in pati...
More Ocuphire Pharma Inc News

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Head office United States
CEO George Magrath
Employees 14
Founded 2018
Website opusgtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today